Tag: PD1CTLA4

Hong Kong

Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023

12 months ago
BusinessL

[ad_1] First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023  /PRNewswire/ — Akeso (9926.HK) published results from three investigator-initiated trials (IITs)…

Hong Kong

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

12 months ago
BusinessL

[ad_1] HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso’s PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/-…

You Missed

Has Sweden got its coronavirus science right? – BBC News

6 months ago
BusinessL

Germany approves legislation easing deportations of rejected asylum seekers

6 months ago
BusinessL

Demographics and geography threaten Singapore with the slow lane – Thailand Business News

6 months ago
BusinessL

Netherlands agribusiness company to build $11M Oconee County facility – GSA Business Report

6 months ago
BusinessL